Kyle A Beckwith , MD, PhD

MD: Ohio State University Columbus, OH, 2018

PhD: Ohio State University Columbus, OH, 2016 (Biomedical Science, Emphasis: Immunology)

B.S.: University of Michigan Ann Arbor, MI, 2009 (Biochemistry)

American Board of Internal Medicine (Certification Date: 08-29-2022 )

Hematology

Hematology and Oncology

Chronic Lymphocytic Leukemia

Leukocytosis

Internal Medicine

Peer Reviewed Publications

Hertlein E.; Beckwith K.A.; Lozanski G.; Chen T.L.; Towns W.H.; Johnson A.J.; Lehman A.; Ruppert A.S.; Bolon B.; Andritsos L.; Lozanski A.; Rassenti L.; Zhao W.; Jarvinen T.M.; Senter L.; Croce C.M.; Symer D.E.; de la Chapelle A.; Heerema N.A.; Byrd J.C. (10-09-2013. ) Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Viv.PLoS ONE, , 8 (10 ) , More Information

Dubovsky J.A.; Beckwith K.A.; Natarajan G.; Woyach J.A.; Jaglowski S.; Zhong Y.; Hessler J.D.; Liu T.M.; Chang B.Y.; Larkin K.M.; Stefanovski M.R.; Chappell D.L.; Frissora F.W.; Smith L.L.; Smucker K.A.; Flynn J.M.; Jones J.A.; Andritsos L.A.; Maddocks K.; Lehman A.M.; Furman R.; Sharman J.; Mishra A.; Caligiuri M.A.; Satoskar A.R.; Buggy J.J.; Muthusamy N.; Johnson A.J.; Byrd J.C. (01-01-2013. ) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lympho.Blood, , 122 (15 ) ,2539-2549 More Information

Zhong Y.; El-Gamal D.; Dubovsky J.A.; Beckwith K.A.; Harrington B.K.; Williams K.E.; Goettl V.M.; Jha S.; Mo X.; Jones J.A.; Flynn J.M.; Maddocks K.J.; Andritsos L.A.; McCauley D.; Shacham S.; Kauffman M.; Byrd J.C.; Lapalombella R. (01-01-2014. ) Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chron.Leukemia, , 28 (5 ) ,1158-1163 More Information

Beckwith K.A.; Frissora F.W.; Stefanovski M.R.; Towns W.H.; Cheney C.; Mo X.; Deckert J.; Croce C.M.; Flynn J.M.; Andritsos L.A.; Jones J.A.; Maddocks K.J.; Lozanski G.; Byrd J.C.; Muthusamy N. (01-01-2014. ) The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel .Leukemia, , 28 (7 ) ,1501-1510 More Information

Liu T.M.; Ling Y.; Woyach J.A.; Beckwith K.; Yeh Y.Y.; Hertlein E.; Zhang X.; Lehman A.; Awan F.; Jones J.A.; Andritsos L.A.; Maddocks K.; MacMurray J.; Salunke S.B.; Chen C.S.; Phelps M.A.; Byrd J.C.; Johnson A.J. (08-08-2015. ) OSU-T315: A novel targeted therapeutic that antagonizes AKT membrane localization and activation of .Blood, , 125 (2 ) ,284-295 More Information

Beckwith K.; Byrd J.; Muthusamy N. (01-01-2015. ) Tetraspanins as therapeutic targets in hematological malignancy: A concise review.Frontiers in Physiology, , 6 (MAR ) , More Information

Gensel J.C.; Wang Y.; Guan Z.; Beckwith K.A.; Braun K.J.; Wei P.; McTigue D.M.; Popovich P.G. (07-08-2015. ) Toll-Like receptors and Dectin-1, a C-type lectin receptor, trigger divergent functions in CNS macro.Journal of Neuroscience, , 35 (27 ) ,9966-9976 More Information

Fraietta J.A.; Beckwith K.A.; Patel P.R.; Ruella M.; Zheng Z.; Barrett D.M.; Lacey S.F.; Melenhorst J.J.; McGettigan S.E.; Cook D.R.; Zhang C.; Xu J.; Do P.; Hulitt J.; Kudchodkar S.B.; Cogdill A.P.; Gill S.; Porter D.L.; Woyach J.A.; Long M.; Johnson A.J.; Maddocks K.; Muthusamy N.; Levine B.L.; June C.H.; Byrd J.C.; Maus M.V. (03-03-2016. ) Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Blood, , 127 (9 ) ,1117-1127 More Information

Hing Z.A.; Mantel R.; Beckwith K.A.; Guinn D.; Williams E.; Smith L.L.; Williams K.; Johnson A.J.; Lehman A.M.; Byrd J.C.; Woyach J.A.; Lapalombella R. (01-01-2015. ) Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic .Blood, , 125 (20 ) ,3128-3132 More Information

Long M.; Beckwith K.; Do P.; Mundy B.L.; Gordon A.; Lehman A.M.; Maddocks K.J.; Cheney C.; Jones J.A.; Flynn J.M.; Andritsos L.A.; Awan F.; Fraietta J.A.; June C.H.; Maus M.V.; Woyach J.A.; Caligiuri M.A.; Johnson A.J.; Muthusamy N.; Byrd J.C. (08-01-2017. ) Ibrutinib treatment improves T cell number and function in CLL patients.Journal of Clinical Investigation, , 127 (8 ) ,3052-3064 More Information

Do P.; Beckwith K.A.; Cheney C.; Tran M.; Beaver L.; Griffin B.G.; Mo X.; Liu Y.; Lapalombella R.; Hertlein E.; Muthusamy N.; Byrd J.C. (05-01-2019. ) Leukemic B cell CTLA-4 suppresses costimulation of T cells.Journal of Immunology, , 202 (9 ) ,2806-2816 More Information

Kittai A.S.; Miller C.; Goldstein D.; Huang Y.; Abruzzo L.V.; Beckwith K.; Bhat S.A.; Bond D.A.; Grever M.R.; Heerema N.A.; Rogers K.A.; Ruppert A.S.; Byrd J.C.; Woyach J.A. (12-09-2021. ) The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treate.Blood, , 138 (23 ) ,2372-2382 More Information

Kittai A.S.; Huang Y.; Beckwith K.A.; Bhat S.A.; Bond D.A.; Byrd J.C.; Goldstein D.; Grever M.R.; Miller C.; Rogers K.A.; Yano M.; Woyach J.A. (01-01-2023. ) Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic l.American Journal of Hematology, , 98 (1 ) ,56-65 More Information